Organization
Elevar Therapeutics, Inc.
2 abstracts
Abstract
Updated results from a phase 2 study of the oral vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor rivoceranib for recurrent or metastatic (R/M) adenoid cystic carcinoma (ACC).Org: Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul National University Hospital, University of Colorado Health Science Center, University of California Los Angeles,
Abstract
Phase 1, randomized, open-label, single-dose, crossover study to evaluate the bioequivalence of four formulations of oral rivoceranib tablets in healthy subjects.Org: Celerion Inc, Tempe, AZ, Elevar Therapeutics, Salt Lake City, UT, Elevar Therapeutics, Inc.,